Subscribe
shutterstock_291526481_mark_van_scyoc
Mark Van Scyoc / Shutterstock.com
19 June 2019Big Pharma

US officials call for review of government-owned IP management

A US congressman and senator have asked the country’s audit institution, the Government Accountability Office (GAO) to review the management of government-owned IP in the health sector.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Gilead claims US government PrEP patents are invalid
20 May 2019   Gilead’s CEO has told a US House of Representatives committee that three Centers for Disease Control HIV prevention patents are invalid.
Americas
Gilead challenges US govt patents on HIV drug Truvada
22 August 2019   Gilead Sciences, the maker of HIV drug Truvada, has asked the US Patent and Trademark Office to review patents granted to the government covering preventative use of the drug.
Generics
China awards generics contracts to lowest bidders
26 September 2019   China’s drug pricing overhaul has seen the average cost of drugs drop by more than half, the country’s Joint Procurement Office announced this week.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
Gilead claims US government PrEP patents are invalid
20 May 2019   Gilead’s CEO has told a US House of Representatives committee that three Centers for Disease Control HIV prevention patents are invalid.
Americas
Gilead challenges US govt patents on HIV drug Truvada
22 August 2019   Gilead Sciences, the maker of HIV drug Truvada, has asked the US Patent and Trademark Office to review patents granted to the government covering preventative use of the drug.
Generics
China awards generics contracts to lowest bidders
26 September 2019   China’s drug pricing overhaul has seen the average cost of drugs drop by more than half, the country’s Joint Procurement Office announced this week.

More on this story

Americas
Gilead claims US government PrEP patents are invalid
20 May 2019   Gilead’s CEO has told a US House of Representatives committee that three Centers for Disease Control HIV prevention patents are invalid.
Americas
Gilead challenges US govt patents on HIV drug Truvada
22 August 2019   Gilead Sciences, the maker of HIV drug Truvada, has asked the US Patent and Trademark Office to review patents granted to the government covering preventative use of the drug.
Generics
China awards generics contracts to lowest bidders
26 September 2019   China’s drug pricing overhaul has seen the average cost of drugs drop by more than half, the country’s Joint Procurement Office announced this week.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York